Italia markets open in 7 hours 29 minutes

Kamada Ltd. (KMDA)

NasdaqGS - NasdaqGS Prezzo differito. Valuta in USD.
Aggiungi a watchlist
5,09-0,01 (-0,20%)
Alla chiusura: 04:00PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente5,10
Aperto5,12
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno5,01 - 5,12
Intervallo di 52 settimane4,08 - 6,53
Volume5.278
Media Volume22.283
Capitalizzazione294,296M
Beta (5 anni mensile)0,24
Rapporto PE (ttm)33,93
EPS (ttm)0,15
Prossima data utili22 mag 2024 - 27 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A12,00
  • GlobeNewswire

    Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

    Following Recent FDA Approval of Technology Transfer Process, CYTOGAM® Manufactured by Kamada at its Facility Now Available for Commercial Sales in U.S.New Clinical Data Highlighting Five-year Real-world Survival Benefits of High Risk CMV Mismatch Lung Transplant Patients Receiving CYTOGAM were Presented at IDWeek 2023Company Establishes Scientific Advisory Board Focused on U.S. Clinical Programs for CYTOGAM REHOVOT, Israel and HOBOKEN, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ

  • GlobeNewswire

    Kamada Provides Corporate Update on its Israel Operations

    REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that while circumstances in Israel are evolving, the Company continues to conduct its business operations in Israel with no effect on business continuity, and its global supply of product

  • GlobeNewswire

    Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

    Funding Strengthens Kamada’s Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a lea